✦ LIBER ✦

Incidence and Risk Factors for Serious Infection in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety

✍ Scribed by KOMANO, Y.; TANAKA, M.; NANKI, T.; KOIKE, R.; SAKAI, R.; KAMEDA, H.; NAKAJIMA, A.; SAITO, K.; TAKENO, M.; ATSUMI, T.; TOHMA, S.; ITO, S.; TAMURA, N.; FUJII, T.; SAWADA, T.; IDA, H.; HASHIRAMOTO, A.; KOIKE, T.; ISHIGATSUBO, Y.; EGUCHI, K.; TANAKA, Y.; TAKEUCHI, T.; MIYASAKA, N.; HARIGAI, M.

Book ID: 118260712
Publisher: Journal of Rheumatology Publishing Company
Year: 2011
Tongue: English
Weight: 337 KB
Volume: 38
Category: Article
ISSN: 0315-162X
DOI: 10.3899/jrheum.101009

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Does Anti-Tumor Necrosis Factor- Therapy

Does Anti-Tumor Necrosis Factor- Therapy Affect Risk of Serious Infection and Cancer in Patients with Rheumatoid Arthritis?: A Review of Longterm Data

✍ KEYSTONE, E. C. 📂 Article 📅 2011 🏛 Journal of Rheumatology Publishing Company 🌐 English ⚖ 355 KB

Anti–tumor necrosis factor α therapy and

Anti–tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis

✍ Sebastian Schneeweiss; Soko Setoguchi; Michael E. Weinblatt; Jeffrey N. Katz; Je 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB 👁 1 views

## Abstract ## Objective To assess the association between the initiation of anti–tumor necrosis factor α (anti‐TNFα) therapy and the risk of serious bacterial infections in routine care. ## Methods This was a cohort study of patients with rheumatoid arthritis (RA) in whom specific disease‐modif

Risk factors for severe infections in pa

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry

✍ J.-E. Gottenberg; P. Ravaud; T. Bardin; P. Cacoub; A. Cantagrel; B. Combe; M. Do 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 2 views

Time-dependent increased risk for seriou

Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis

✍ Ryoko Sakai; Yukiko Komano; Michi Tanaka; Toshihiro Nanki; Ryuji Koike; Hayato N 📂 Article 📅 2012 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 135 KB

Individualized monitoring of drug bioava

Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab

✍ Klaus Bendtzen; Pierre Geborek; Morten Svenson; Lotta Larsson; Meliha C. Kapetan 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 2 views

## Abstract ## Objective Infliximab, an anti–tumor necrosis factor α (anti‐TNFα) antibody, is effective in the treatment of several immunoinflammatory diseases. However, many patients experience primary or secondary response failure, suggesting that individualization of treatment regimens may be b

Tumor necrosis factor therapy and the ri

Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: A meta-analysis of randomized controlled trials

✍ Andrew E. Thompson; Scott W. Rieder; Janet E. Pope 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB 👁 2 views